1. Home
  2. TII vs IKT Comparison

TII vs IKT Comparison

Compare TII & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Titan Mining Corporation

TII

Titan Mining Corporation

N/A

Current Price

$1.92

Market Cap

198.5M

Sector

N/A

ML Signal

N/A

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

N/A

Current Price

$1.52

Market Cap

218.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TII
IKT
Founded
2012
2008
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
198.5M
218.4M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
TII
IKT
Price
$1.92
$1.52
Analyst Decision
Buy
Strong Buy
Analyst Count
2
10
Target Price
★ $6.50
$5.55
AVG Volume (30 Days)
199.5K
★ 684.3K
Earning Date
11-12-2026
11-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 57.76
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$22.91
N/A
Revenue Next Year
N/A
$33.33
P/E Ratio
$25.66
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.81
$1.40
52 Week High
$5.65
$2.61

Technical Indicators

Market Signals
Indicator
TII
IKT
Relative Strength Index (RSI) 35.71 37.66
Support Level $1.88 N/A
Resistance Level $2.47 $1.72
Average True Range (ATR) 0.12 0.11
MACD 0.02 0.01
Stochastic Oscillator 19.46 24.24

Price Performance

Historical Comparison
TII
IKT

About TII Titan Mining Corporation

Titan Mining Corp is a Canadian natural resources company. The company is engaged in the acquisition, exploration, development, and extraction of mineral properties. The company owns an interest in the Empire State Mine in Northern New York State, United States, and Kilbourne Graphite Project. The Company operates one reportable segment, mineral production and exploration in the United States.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Share on Social Networks: